Reports Q3 revenue $2.26K, consensus $9.75K. Says on track for initial prescription fulfillment of Sildenafil Cream in December through a 503B-registered outsourcing facility, in discussions with FDA ongoing regarding endpoint assessment for Phase 3 clinical studies of Sildenafil Cream, 3.6%. “Dare is executing a disciplined, multi-pronged value creation strategy – preparing to generate revenue from DARE to PLAY(TM) Sildenafil Cream beginning in December, while advancing a pipeline that spans both clinical innovation and near-term commercial solutions,” said Sabrina Martucci Johnson, President and CEO of Dare Bioscience (DARE).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Dare Bioscience to host webinar on the DARE to PLAY
- Is DARE a Buy, Before Earnings?
- Dare Bioscience to receive up to $300,000 to conduct landscape review
- Daré Bioscience Advances Progesterone Delivery Study for Preterm Birth Prevention
- Daré Bioscience’s Ovaprene Study: A New Era in Contraceptive Innovation